Russell Investments Group Ltd. Buys 94,545 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Russell Investments Group Ltd. grew its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 93.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 195,906 shares of the biopharmaceutical company’s stock after purchasing an additional 94,545 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.11% of Sangamo Therapeutics worth $345,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Penserra Capital Management LLC bought a new position in shares of Sangamo Therapeutics during the first quarter valued at $66,000. Lazard Asset Management LLC raised its stake in shares of Sangamo Therapeutics by 37.9% during the first quarter. Lazard Asset Management LLC now owns 12,168 shares of the biopharmaceutical company’s stock valued at $70,000 after acquiring an additional 3,342 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of Sangamo Therapeutics by 848.9% during the fourth quarter. Quadrant Capital Group LLC now owns 12,734 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 11,392 shares during the last quarter. AlphaCrest Capital Management LLC increased its stake in shares of Sangamo Therapeutics by 25.4% in the first quarter. AlphaCrest Capital Management LLC now owns 14,419 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 2,919 shares during the period. Finally, Handelsbanken Fonder AB acquired a new stake in shares of Sangamo Therapeutics in the fourth quarter valued at about $48,000. 59.81% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

SGMO has been the subject of several recent research reports. Royal Bank of Canada decreased their price target on Sangamo Therapeutics from $8.00 to $6.00 and set an “outperform” rating for the company in a research note on Wednesday, August 9th. Barclays reduced their price objective on shares of Sangamo Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 9th. Wells Fargo & Company dropped their price objective on Sangamo Therapeutics from $5.00 to $4.00 and set an “overweight” rating on the stock in a research note on Thursday, August 10th. StockNews.com raised Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, July 14th. Finally, Wedbush lowered their price objective on shares of Sangamo Therapeutics from $16.00 to $10.00 and set an “outperform” rating for the company in a research note on Friday, August 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.80.

Sangamo Therapeutics Trading Up 1.4 %

NASDAQ SGMO opened at $0.98 on Tuesday. The company has a market cap of $174.03 million, a P/E ratio of -0.82 and a beta of 1.10. The company has a fifty day simple moving average of $1.18 and a 200 day simple moving average of $1.53. Sangamo Therapeutics, Inc. has a 12-month low of $0.77 and a 12-month high of $5.88.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.02). The business had revenue of $6.84 million for the quarter, compared to the consensus estimate of $22.33 million. Sangamo Therapeutics had a negative net margin of 90.86% and a negative return on equity of 50.17%. Sell-side analysts predict that Sangamo Therapeutics, Inc. will post -0.84 EPS for the current year.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.